Autolus Therapeutics (NASDAQ:AUTL) Sets New 12-Month Low – Here’s Why

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price hit a new 52-week low during trading on Wednesday . The stock traded as low as $2.07 and last traded at $2.25, with a volume of 1651083 shares trading hands. The stock had previously closed at $2.18.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Friday, November 15th. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, December 5th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $10.40.

Autolus Therapeutics Price Performance

The company has a market capitalization of $612.02 million, a price-to-earnings ratio of -1.90 and a beta of 1.99. The stock has a 50 day simple moving average of $3.23 and a two-hundred day simple moving average of $3.73.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the prior year, the firm posted ($0.26) EPS. Equities research analysts predict that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Institutional Trading of Autolus Therapeutics

A number of large investors have recently made changes to their positions in the company. Wellington Management Group LLP lifted its stake in Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after buying an additional 6,330,392 shares during the last quarter. FMR LLC increased its holdings in shares of Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after acquiring an additional 5,478,706 shares during the period. Erste Asset Management GmbH purchased a new stake in Autolus Therapeutics in the 3rd quarter valued at $708,000. Renaissance Technologies LLC boosted its stake in Autolus Therapeutics by 253.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company’s stock worth $3,985,000 after purchasing an additional 821,156 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in Autolus Therapeutics during the 3rd quarter worth $1,082,000. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.